retatrutide trial weight loss data Lilly's triple agonist achieves 16.8% in phase 3 Retatrutide Weight Loss Results:Trial Data

When evaluating frozen meal options, GLP-1 users should carefully scrutinize the nutrition label, focusing specifically on the

One of many more episodes to come on this hot topic

Eli Lilly's next-generation obesity treatment "retatrutide" has ignited competition for next-generation obesity drugs, confirming a weight loss effect of up to 28% in phase 3 clinical trials

Use our simple checklist to create a nutrient routine for GLP-1 users, avoid overlaps and create a foundation for nutritional health.

Have cravings on a higher dose GLP-1

New research presented at the Endocrine Society's ENDO 2026 meeting is generating interest among clinicians who manage obesity, testosterone deficiency, and male reproductive health